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ABSTRACT
Nucleotide-metabolizing ectoenzymes are endowed with an extracellular catalytic 
domain, which is involved in regulating the extracellular nucleotide/nucleoside 
balance. The tumor microenvironment contains high levels of adenosine (ADO) 
generated by this enzymatic network, thus promoting tumor growth by inhibiting 
anti-tumor immune responses. ADO inhibition in melanoma murine models limits 
tumor metastases and restores anti-tumor immune responses.
This work investigates the expression and function of ectoenzymes in primary 
human melanoma cell lines. All of latter cells expressed CD38, CD39, CD73, and 
CD203a/PC-1, and produced ADO from AMP and NAD+. Melanoma cells inhibited 
T cell proliferation through an ADO-dependent mechanism, since such inhibition was 
reverted using CD38/CD73 specific inhibitors.
Melanoma cells abolished the function of effector memory, central memory and 
reduced naïve CD4+ T cell proliferation. Accordingly, phosphorylation of S6 ribosomal 
protein, p38 and Stat1 was lower in activated memory cells than in naïve CD4+ T 
lymphocytes. Melanoma cells also inhibited proliferation of naïve, memory and -to a 
lesser extent- of effector CD8+ T cells. These different inhibitory effects correlated 
with distinct patterns of expression of the ADO receptor A2a and A2b. These results 
show that primary human melanoma cell lines suppress in vitro T cell proliferation 
through an adenosinergic pathway in which CD38 and CD73 play a prominent role.
INTRODUCTION
The adenosine (ADO) nucleoside is generated from 
the catabolism of several nucleotides (i.e. ATP, ADP, 
ADPR and AMP) or of NAD+ by nucleotide-metabolizing 
ectoenzymes. These ectoenzymes are expressed on 
the outer membrane of numerous cell populations 
and exert their enzymatic activity in the extracellular 
milieu. The canonical pathway of ADO production 
starts from CD39, an ecto-nucleoside triphosphate 
diphosphohydrolase (NTPDase), which converts ATP to 
ADP and then into AMP. The latter molecule is further 
converted to ADO by the 5’-nucleotidase (5’-NT) 
CD73 [1]. An alternative pathway has been recently 
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demonstrated. The key molecule is CD203a/PC-1, since it 
converts both ADPR (generated from NAD+ by CD38) or 
ATP to AMP, that is subsequently metabolized into ADO 
by CD73 [2, 3].
Under physiological conditions, the concentration 
of ADO in the extracellular environment is normally 
very low. However, the presence of high levels of 
ADO in pathological conditions, such as tissue injury, 
ischemia, hypoxia, inflammation, trauma and cancer 
[4] activates the specific adenosine receptors (ADOR) 
on immune cells, giving rise to immunosuppressive 
effects [5, 6]. Specific ligation of ADORA2a inhibits 
NK cell cytotoxicity and IFN-γ release [4], while 
engagement of ADORA2a and ADORA2b dampens 
T lymphocyte effector functions (mainly cytotoxicity 
and cytokine release [4, 7, 8]. Moreover, ADO inhibits 
macrophage activation by interacting with ADORA2a 
and induces M2 polarization via ADORA2b. Finally, 
activation of ADORA2b hinders dendritic cells 
maturation and differentiation, leading to defective 
antigen presentation [4].
ADO is released in the neoplastic microenvironment 
either by CD73+ tumor cells or by CD73+ infiltrating 
leukocyte subsets, such as myeloid-derived suppressor 
cells (MDSC) or regulatory T cells (Treg) [4, 9, 10]. 
Several studies reported that elevated expression of CD73 
by tumor cells correlated to a worse prognosis of patients 
with different types of solid tumors, such as breast cancer 
[11], melanoma [12, 13], prostate cancer [14] and gastric 
carcinoma [15]. High concentrations of ADO are present 
in the tumor microenvironment also in murine models 
[16]. In line with this, blockade or inhibition of CD73 
[6, 10, 17–21], CD39 [22, 23] and ADORs [6, 11, 24–27] 
in the same models resulted in the reduction of tumor 
growth and metastasis.
Primary cell lines previously generated in our 
laboratory from melanoma biopsies [28] inhibit NK cell 
functions through the production of immunosuppressive 
molecules such as IDO and PGE2 [29].
So far, CD73 is the only component of the 
ectoenzymatic pathways of ADO production whose 
expression has been reported in human melanoma 
cells [12]. No information is available regarding the 
expression and function of the other ectoenzymes 
involved (CD38, CD39 and CD203a/PC-1). Several 
groups have demonstrated that melanoma cells can inhibit 
T cell function, mainly via PD-1/PDL-1 interaction 
[30–32]. Interestingly, PD-1 expression on malignant 
cells is induced by hypoxia [31], similarly to what 
observed for ADO. Moreover, both molecules can be 
expressed or released also by cells infiltrating the tumor 
microenvironment (i.e. Treg) [32].
This study demonstrated that i) high amounts 
of ADO are generated by malignant melanoma 
cells through both the canonical and non-canonical 
ectoenzymatic pathways, and ii) ADO produced by 
melanoma cells exerts differential influence on the 
T lymphocyte populations involved in the anti-tumor 
immune response.
RESULTS
Melanoma cell lines express nucleotide-
metabolizing ectoenzymes
The first step in this study was to analyse the 
expression of a panel of ectoenzymes on six primary 
melanoma cell lines (MECA, METRAV, MEPA, MECO, 
MEMO and MEOL), using a commercially available 
melanoma cell line (FO1) as control.
Figure 1, panel A, shows that CD39 was highly 
expressed by two primary cell lines (METRAV and 
MECO, MRFI 196.63 and 96.13, respectively), but only 
moderately expressed in the other cell lines (MRFI range 
2.07–7.18). CD38 was expressed by all cell lines analyzed 
(MRFI range 6.36–9.35), while CD157 expression was 
barely detectable (MRFI range 1.07–2.48). CD203a/PC-1 
was expressed by all melanoma cell lines (MRFI range 
1.77–6) with a high expression on METRAV (MRFI 6), 
MECO (MRFI 4.14), and FO-1 cell lines. The expression 
of CD73, the enzyme that leads to ADO production in 
both pathways, was very high in all cell lines examinated 
(MRFI range 14.17–849.13).
These observations indicated that melanoma cells are 
equipped with the complete set of molecules constituting 
the canonical (CD39/CD73) and alternative (CD38/CD157/
CD203a(PC-1)/CD73) pathways for ADO production.
ADO production by primary melanoma cell lines
Next, we asked whether the ectoenzyme pathways 
expressed by melanoma cells were functional. To this end, 
we selected two CD39high/CD203a(PC-1)high (METRAV, 
MECO) and two CD39low/CD203a(PC-1)low (MECA and 
MEOL) melanoma cell lines and evaluated the production 
of ADO in cell culture supernatants upon addition of ATP, 
NAD+ or AMP (100 μM) as substrates. Cells were cultured 
in the presence or absence of EHNA, an inhibitor of ADO 
deaminase enzyme.
Figure 1, panel B, shows that the highest production 
of ADO was obtained when AMP served as the 
substrate (mean nmol ADO/30 min ± SD: 4.05 ± 0.28). 
Furthermore, ADO production was significantly increased 
in the presence of EHNA (7.16 ± 0.32, p = 0.01). These 
results indicated that ADO is produced and then partially 
consumed by ADO deaminase. In contrast, ADO 
production was low when using ATP (0.37 ± 0.41) or 
NAD+ (0.017 ± 0.02) as substrates. In both cases, ADO 
production was almost unaffected by EHNA treatment. 
These observations suggest that CD73 is functional on 
melanoma cells, since AMP is converted to ADO with 
high efficiency. The low levels of ADO production 
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Figure 1: Panel A. Ectoenzyme expression on melanoma cells lines. The expression of CD39, CD38, CD157, CD203a/PC-1 and 
CD73 was assessed by flow cytometry line on the 6 primary melanoma cell lines (METRAV, MECA, MECO, MEPA, MEMO, MEOL) 
and on the FO1 melanoma cell line. Data are expressed as MRFI. Panel B. ADO production by melanoma cell lines. ADO production was 
investigated by HPLC in supernatants from four melanoma cell lines incubated with different substrates (ATP, NAD+ and AMP at 100 μM), 
in the presence (grey bars) or absence (white bars) of EHNA. Data are expressed as nmol ADO/30 min ± SD. p values are indicated where 
differences are statistically significant.
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by melanoma cells observed after providing NAD+ as 
substrate may indicate that enzymatic function either of 
CD38 or CD203a/PC-1, which converts ADPR produced 
from NAD+ by CD38 to AMP, is inefficient. The latter 
possibility appears to be more likely, since the production 
of ADO from ATP (initiated by CD39) is also low. It is fair 
to assume that enzymatic activities of these molecules in 
melanoma cells are limited.
We then turned our attention to analyse the kinetics 
of ADO production, using different concentrations of 
ATP, AMP, NAD+ and ADPR (20 and 50 μM). To this 
aim, we selected one CD39highCD203a(PC-1)high (MECO, 
Figure 2, panels A, C, E and G) and one CD39lowCD203a/
PC-1low (MEOL, Figure 2, panels B, D, F, and H) 
melanoma cell line.
The highest level of ADO production was achieved 
using AMP as substrate in both cell lines, with a peak at 
30 min using 20 μM AMP (MECO 6 nmol ADO, MEOL 
4.2 nmol ADO) and a linear increase using 50 μM AMP 
(MECO 33.17 nmol ADO/45 min, MEOL 38.2 nmol 
ADO/45 min) (Figure 2, panels A and B). ADO production 
from NAD+ or ADPR was extremely low. Both cell lines 
peaked at 5 min using 50 μM NAD+ (MECO 0.19 nmol 
ADO, MEOL 0.31 nmol ADO) and at 30 min using 
20 μM NAD+ (MECO 0.63 nmol ADO, MEOL 0.72 nmol 
ADO). In contrast, MECO peaked at 30 min using 20 μM 
(0.78 nmol ADO) or 50 μM ADPR (0.17 nmol ADO), 
whereas MEOL displayed a peak at 5 min using 20 μM 
ADPR (0.59 nmol ADO) and another peak at 30 min using 
50 μM ADPR (0.41 nmol ADO). For both cell lines, the 
highest production of ADO was achieved when using the 
lowest concentration of substrates, thus suggesting that 
their enzymatically active sites may be inactivated and/or 
saturated by ADPR or NAD+ at high concentrations.
ADO production was similar in the two melanoma 
cell lines when using 20 μM ATP as substrate: the peak 
was reached in 5 min in MECO (2.89 nmol ADO) and 
in 30 min in MEOL (3.96 nmol ADO) followed by 
a slow decline in both. In contrast, the use of 50 μM 
ATP led to different results: MECO displayed a peak 
at 30 min (7.1 nmol ADO) followed by rapid decrease, 
while MEOL showed a linear increase (4.32 nmol 
ADO/45 min). This different kinetics reflect the different 
expression of CD39 and CD203a(PC-1) by the two cell 
lines (see Figure 1, panel A).
Melanoma cells inhibited T cell proliferation
To test the possibility that melanoma cell lines 
inhibited T cell proliferation through ADO production, 
we evaluated the proliferation of CD4+ and CD8+ T cells 
activated by anti-CD3/anti-CD28 beads in the presence 
or absence of primary melanoma cells. The effect 
was quantified using a CFSE dilution assay. In some 
experiments, melanoma cells were pre-treated with 
kuromanin (inhibitor of CD38), dipyridamole (inhibitor 
of nucleoside transporter), α-β-methyl ADP (inhibitor of 
CD73) and β-γ-methyl ATP (inhibitor of CD203a/PC-1), 
to assess the individual contribution of each ectoenzyme 
in inhibiting T cell proliferation.
Proliferation of CD4+ T cells (% of proliferating 
cells ± SD: 84.06 ± 20.27) was significantly inhibited 
in the presence of melanoma cells at 1:8 (29 ± 17.1, 
p = 0.0001) or 1:16 (38.9 ± 11, p = 0.0008) 
melanoma:CD4+ T cell ratios (Figure 3, panel A). T cell 
proliferation was significantly restored in the presence of 
kuromanin (45.06 ± 18.1, p = 0.02) and α-β-methyl ADP 
(47.8 ± 13.54, p = 0.009). These findings indicate that 
CD38 and CD73 play key roles in the inhibition of T cell 
proliferation.
In order to assess whether inhibition of CD4+ 
T cell proliferation is mediated by the release of soluble 
factors by melanoma cells, the same experiments were 
performed using a transwell system. CD4+ T lymphocytes 
proliferation (% of proliferating cells ± SD: 84.06 ± 20.27) 
was significantly inhibited in the presence of melanoma 
cells either at 1:8 (24.28 ± 7.75, p = 0.0008) or 1:16 
(36.3 ± 6.89, p = 0.005) melanoma:CD4+ T cell ratios. 
We conclude that the inhibition observed was prevalently 
mediated by soluble factors (Figure 3, panel B).
Similar experiments were performed using CD8+ T 
lymphocytes. CD8+ T cell proliferation (% of proliferating 
cells ± SD: 68.35 ± 16.95) was significantly inhibited in 
the presence of melanoma cells at 1:16 melanoma:CD8+ 
T cells ratio (12.61 ± 8.9, p < 0.0001, Figure 3, panel C). 
The observed inhibition was partially reverted by pre-
treating melanoma cells with kuromanin (22.05 ± 12.1, 
p = 0.04) and α-β-methyl ADP (28.36 ± 6.2, p = 0.0005). 
The roles of CD38 and CD73 were therefore confirmed 
on this population, too. In addition, pre-treatment of 
melanoma cells with dipyridamole significantly increased 
the inhibition of T cell proliferation (4.1 ± 3.7, p = 0.01). 
This inhibitor is reported to increase extracellular 
concentrations of ADO by inhibiting nucleoside 
transporter. Apparently, ADO is more effective on CD8+ 
than on CD4+ T cell populations.
Additional experiments were performed to 
demonstrate unambiguously that the inhibition of T cell 
proliferation induced by melanoma cells was mediated 
by ADO. To this end, T cells were pre-treated with 
specific antagonists of ADORA1 (PSB36), ADORA2a 
(SCH58261) and ADORA2b (PSB1115) before being 
cultured with melanoma cells. As shown in Figure 3, panel 
D, proliferation of CD4+ T cells was significantly restored 
in the presence of PSB36 (% of variation ± SD: 100 vs 
136.4 ± 12.84, p = 0.03) and SCH58261 (100 vs 114.2 ± 
13.03, p = 0.03), but not of PSB1115 (100 vs 82.23 ± 
15.46). In contrast, proliferation of CD8+ T cells was 
significantly restored in the presence of SCH58261 (% 
of variation ± SD: 100 vs 116.1 ± 13.54, p = 0.01) and 
PSB1115 (100 vs 120.1 ± 16.43, p = 0.01), but not of 
PSB36 (100 vs 106.3 ± 65.45). Taken together, these data 
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Figure 2: Kinetics of ADO production by melanoma cell lines. ADO production was investigated in supernatants collected at 5, 
30 and 45 min from MECO (panel A-C-E-G) and MEOL (panel B-D-F-H) cell lines treated with AMP (panel A-B), ATP (panel C-D), 
NAD+ (panel E-F) and ADPR (panel G-H) 20 (continuous lines) or 50 (dotted lines) μM. Data are expressed as nmol ADO.
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Figure 3: Inhibition of T cell proliferation by melanoma cell lines. Panel A. CD4+ T cells stimulated with anti-CD3/CD28 
beads (white bar) were co-cultured with melanoma cell lines at melanoma:T cell ratios of 1:8 (grey bar), 1:16 (light grey bar) or 1:8 in the 
presence of inhibitors (stripped bars). T cell proliferation was assessed by CFSE dilution using a flow cytometer. Results are expressed 
as % of proliferating cells. Mean of 12 experiments ± SD is shown. p values are indicated where differences are statistically significant. 
Panel B. CD4+ T cells stimulated with anti-CD3/CD28 beads (white bar) were co-cultured with melanoma cell lines at melanoma:T cell 
ratios of 1:8 (grey bar) or 1:16 (light grey bar) using a transwell system. T cell proliferation was assessed by CFSE dilution using a flow 
cytometer. Results are expressed as % of proliferating cells. Mean of 6 experiments ± SD is shown. p values are indicated where differences 
are statistically significant. Panel C. CD8+ T cells stimulated with anti-CD3/CD28 beads (white bar) were co-cultured with melanoma cell 
lines at melanoma:T cell ratios of 1:16, in the presence (stripped bars) or absence (grey bar) of inhibitors. T cell proliferation was assessed 
by CFSE dilution using a flow cytometer. Results are expressed as % of proliferating cells. Mean of 8 experiments ± SD is shown. p values 
are indicated where differences are statistically significant.
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confirmed that the inhibition of proliferation was mediated 
by ADO, mainly through the interaction with ADORA1 
and A2a on CD4+ T cells, and with ADORA2a and A2b 
in CD8+ T cells.
Central and effector memory T cells are 
the main targets of the inhibitory effects of 
melanoma cells
The next step was to investigate whether melanoma 
cells might have different effects on the T cell subsets. 
Co-culture experiments using each purified T cell subset 
at 1:16 melanoma: T cell ratio were performed to answer 
this issue.
The inhibitory effects exerted by melanoma 
cells were tested on CD4+CD27+CD45RA+ naïve 
T cells, CD4+CD27+CD45RA− central memory T cells 
and CD4+CD27−CD45RA− effector memory T cells. 
Terminally differentiated effector CD4+CD27−CD45RA+ 
T cells were not included because of their limited 
presence in the peripheral blood of normal individuals 
(range 1–5%). Inhibition of CD4+ T cell proliferation in 
the presence of melanoma cell lines resulted significantly 
lower in naïve cells (% of inhibition ± SD: 5.82 ± 5.04) 
than in effector memory (37.42 ± 14.86, p = 0.0048) and 
central memory (25.17 ± 5.7, p = 0.0079) CD4+ T cells 
(Figure 4, panel A).
Next, we asked whether these differential effects 
might be related to a different expression of ADORs in 
these different subsets. ADORA1 was expressed similarly 
in the three different subsets (Figure 4, panel B). In contrast, 
ADORA2a and ADORA2b display a peculiar pattern of 
expression: higher in naïve cells (% positive cells ± SD: 
ADORA2a 32.16 ± 15.51; ADORA2b 71.69 ± 7.04) 
but lower in effector memory (ADORA2a 10.59 ± 8.06, 
p = 0.05; ADORA2b 32.94 ± 22.75, p = 0.05) and central 
memory (ADORA2a 2.61 ± 1.57, p = 0.05; ADORA2b 
11.23 ± 2.18, p = 0.05) CD4+ T cells (Figure 4, panel B).
The effects of co-colture with melanoma cells 
was next evaluated on CD8+CD27+CD45RA+ naïve 
T cells, CD8+CD27+CD45RA− memory T cells and 
CD8+CD27−CD45RA− effector T cells. The percent 
inhibition of CD8+ T cell proliferation in the presence of 
melanoma cell lines was significantly lower in effector 
cells (% of inhibition ± SD: 1.83 ± 3.17) than in memory 
(22.38 ± 4.15, p = 0.005) and naive (44.12 ± 11.9, p = 0.03) 
CD8+ T cells (Figure 5, panel A). The expression of 
ADORs was also analyzed on the different CD8+ T cell 
subsets. CD8+ T cell subsets expressed similarly low levels 
of ADORA1. In contrast, ADORA2a and ADORA2b 
expression was higher in effector cells (% of positive cells 
± SD: ADORA2a 35.54 ± 7.27; ADORA2b 39.13 ± 4.74) 
than in memory (ADORA2a 7.16 ± 2.78, p = 0.01; 
ADORA2b 3.58 ± 0.94, p = 0.01) and naive (ADORA2a 
2.35 ± 0.23, p = 0.01; ADORA2b 6.52 ± 1.25, p = 0.01) 
CD8+ T cells (Figure 5, panel B).
Overall, these findings support the view that the 
melanoma cells are characterized by a selective ability 
to inhibit different subsets of CD4+ and CD8+ T cells. 
Furthermore, each subset is characterized by a particular 
pattern of expression of ADORA2a and A2b.
Effects of ADO-mediated intracellular signaling 
in naïve and memory CD4+ T lymphocytes
We hypothesize that the inhibition of proliferation 
induced by ADO in naïve and memory T cells might 
reflect distinct ADO-mediated modulation of intracellular 
signaling in the two cell populations. We therefore 
investigated the phosphorylation of multiple key factors 
involved in cell signaling by treating naïve and memory 
CD4+ T cells with anti-CD3/anti-CD28 beads, in the 
presence (or absence) of ADO, using a specific antibody 
array. A scheme of this array is reported in Figure 6, 
panel A, while the list of proteins analyzed is reported in 
the corresponding figure legend.
Figure 6, panel B (representative experiment) and 
C (mean of 4 independent experiments) shows that ADO 
inhibits the phosphorylation of AMPK-α (% fold increase, 
mean ± SD: naïve −16.74 ± 2.44, memory −35.11 ± 12.02), 
S6 ribosomal protein (naïve −13.08 ± 1.14, 
memory −32.21 ± 8.02), BAD (naïve −10.96 ± 3.68, 
memory −24.74 ± 6.54), caspase-3 (naïve −12.89 ± 8.04, 
memory −11.61 ± 4.71), PRAS40 (naïve −32.29 ± 9.3, 
memory −59.1 ± 18.23) and STAT1 (naïve −4.38 ± 2.07, 
memory −23.76 ± 7.5). Conversely, p38 phosphorylation 
was increased in naïve (% of fold increase, mean ± SD: 
15.43 ± 7.87) and inhibited in memory (-20.87 ± 8.8) 
CD4+ T cells (Figure 6, panel B and C).
The phosphorylation profiles of S6 ribosomal 
protein, p38 and Stat1 were significantly different in 
naïve and memory CD4+ T cells (highlighted in Figure 6, 
panel B, p = 0.01). Memory T cells displayed lower 
phosphorylation levels of these factors; this may be 
consistent with the stronger inhibition of proliferation 
induced by ADO in this subset, as compared to naïve 
counterparts.
Since mTOR pathway is essential for T lymphocyte 
proliferation, we further investigated the phosphorylation 
of regulatory associated protein of mTOR (Raptor) and 
rapamycin-insensitive companion of mTOR (Rictor) on 
the same protein extracts from naïve and memory CD4+ 
T cells. As shown in Figure 7, panel A (a representative 
experiment) and B (mean of four different experiments), 
the phosphorylation of Rictor was unaffected by ADO 
treatment, either in naïve (relative density: ctr 0.3 ± 0.05, 
ADO 0.29 ± 0.08) or memory (ctr 0.77 ± 0.13, ADO 
0.62 ± 0.09) CD4+ T cells. Conversely, phosphorylation 
of Raptor was significantly increased by ADO treatment 
in naïve (ctr 0.18 ± 0.03, ADO 0.35 ± 0.04, p = 0.01) 
but not in memory (ctr 1.28 ± 0.18, ADO 1.10 ± 0.21) 
CD4+ T cells. These data further support the concept that 
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Figure 4: Inhibition of cell proliferation and expression of ADO receptors in CD4+ T cell subsets. Panel A. Naïve (white bars),  
effector memory (light grey bars) and central memory (grey bars) CD4+ T lymphocytes were isolated and stimulated with anti-CD3/
CD28 beads in the presence or absence of melanoma cell lines at 1:16 melanoma:T cell ratio. T cell proliferation was assessed by CFSE 
dilution using a flow cytometer. Results are expressed as % of inhibition, calculated as follows: % of proliferating cells in the absence 
of melanoma cells - % of proliferating cells in the presence of melanoma cells/% of proliferating cells in the absence of melanoma cells. 
Mean of 6 experiments ± SD is shown. p values are indicated where differences are statistically significant. Panel B. ADORA1, A2a, A2b 
was investigated by flow cytometry on purified CD4+ T cells, gating on naïve (white bars), effector memory (light gray bars) and central 
memory (grey bars). Data are expressed as % of positive cells. Mean of four different experiments ± SD is shown. p values are indicated 
where differences are statistically significant.
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Figure 5: Inhibition of cell proliferation and expression of ADO receptors in CD8+ T cell subsets. Panel A. Naïve (white bars),  
effector (light grey bars) and memory (grey bars) CD8+ T lymphocytes were isolated and stimulated with anti-CD3/CD28 beads in the 
presence or absence of melanoma cell lines at 1:16 melanoma:T cell ratio. T cell proliferation was assessed by CFSE dilution using a flow 
cytometer. Results are expressed as % of inhibition, calculated as follows: % of proliferating cells in the absence of melanoma cells - % 
of proliferating cells in the presence of melanoma cells/% of proliferating cells in the absence of melanoma cells. Mean of 6 experiments  
± SD is shown. p values are indicated where differences are statistically significant. Panel B. ADORA1, A2a, A2b was investigated by flow 
cytometry on purified CD8+ T cells, gating on naïve (white bars), effector (light gray bars) and memory (grey bars). Data are expressed  
as % of positive cells. Mean of four different experiments ± SD is shown. p values are indicated where differences are statistically significant.
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Figure 6: Evaluation of intracellular signaling in naïve and memory CD4+ T cells. Intracellular signaling has been evaluated 
in naïve and memory CD4+ T cells stimulated with anti-CD3/CD28 beads in the presence (ADO) or absence (CTR) of ADO, using an 
intracellular signaling array kit. Target map is shown in panel A. and include the following proteins: 1) positive control, 2) negative 
control, 3) ERK1/2, 4) Stat1, 5) Stat3, 6) and 7) Akt, 8) AMPKα, 9) S6 ribosomal protein, 10) mTOR, 11) HSP27, 12) BAD, 13) p70 S6 
kinase, 14) PRAS40, 15) p53, 16) p38, 17) SAPK/JNK, 18) PARP, 19) caspase-3, 20) GSK-3β. A representative experiment is shown in 
panel B. Proteins whose modulation was significantly different between naïve and memory T cells (Stat1, S6 ribosomal protein and p38) 
are highlighted. Panel C. shows modulation of phosphorylation of different factors in the presence of ADO in naïve (white bars) and 
memory (grey bars) CD4+ T cells. Results are expressed as % of fold increase, calculated as follows: ((relative intensity of spot obtained in 
the presence of ADO - relative intensity of spot obtained in the absence of ADO)/relative intensity of spot obtained in the absence of ADO)) 
*100. Mean ± SD of four independent experiments is shown.
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intracellular signalling is differentially modulated by ADO 
in naïve and memory T cells.
DISCUSSION
Several independent studies indicate that the 
production of ADO is a feature acquired by different 
solid tumors, and that the small or virtual spaces at the 
interface between the tumor and host organs, referred to 
as the microenvironment, are characterized by high levels 
of ADO [4, 5, 16, 24, 33, 34]. These attributes are now 
considered to make up a refined strategy on the part of 
tumor cells to exploit the ADO and its uptake by immune 
effector cells to circumvent immune defences [5, 6]. ADO 
can be produced from ATP or alternatively from NAD+ 
which are metabolized by a panel of ectoenzymes present 
on the surface of tumor cells and expressed by local or 
infiltrating effector lymphocytes [25, 33, 35].
Separate groups have demonstrated that CD73 
promotes tumor growth in experimental tumor models 
[6, 18], including melanoma. However, CD73 knock-
out mice are resistant to tumor metastasis and display 
a potent anti-tumor immune response [18]. The CD73 
gene is methylated in normal melanocytes and primary 
melanoma lesions, but it is epigenetically up-regulated 
during melanoma progression. This further support a role 
of this molecule during tumorigenesis [13].
Given the functions of ADO in the immune system, 
the set of the different receptors specific for ADO is crucial 
both for the growth of tumor and for tumor-mediated 
immunosuppression; indeed, metastases are limited when 
these receptors are blocked [25] or knocked-out [24]. 
Whether melanoma cells can directly release ADO and 
whether ADO can inhibit the functions of T lymphocytes 
is still unclear.
This study demonstrates that primary melanoma 
cells are equipped with both the canonical (CD39/CD73) 
and the alternative [2, 3] (CD38/CD157/CD203a(PC-1)/
CD73) ectoenzymatic pathways for producing ADO at the 
interface between tumor and host. All these ectoenzymes 
are functional in the primary cell lines of human 
melanoma analyzed. This finding shows that these cells 
may use ATP and NAD+ to produce ADO. CD73 operates 
as a sort of checkpoint. As a matter of fact, the maximum 
release of ADO was obtained after adding AMP, which 
suggests that CD73 is the most active of the ectoenzymes. 
This is also corroborated by the finding that CD73 is the 
most expressed on all melanoma cells analyzed.
The variability in ADO production observed 
after providing different substrates is related to the 
heterogeneous expression of ectoenzymes by primary 
melanoma cells. Indeed, the maximum ADO production 
from ATP (a substrate for CD39 and CD203a/PC-1) and 
ADPR (a substrate for CD203a/PC-1) was achieved 
Figure 7: Evaluation of mTOR associated proteins in naïve and memory CD4+ T cells. Phosphorylation of Rictor and 
Raptor has been evaluated by western blot analysis in naïve and memory CD4+ T cells stimulated with anti-CD3/CD28 beads in the 
presence (ADO, grey bars) or absence (CTR, white bars) of ADO. A representative experiment is shown in panel A. Mean of four different 
experiments ± SD is shown in Panel B. Results are expressed as relative density, calculated as follows: (density of the specific protein/
density of housekeeping protein).
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in CD39highCD203a/PC-1high cell lines. Consistent with 
this observation, ADO production from AMP and NAD+ 
was comparable in all cell lines expressing similar levels 
of CD73 and CD38 (specific enzymes for AMP and NAD+ 
respectively).
The immunosuppression exerted by ADO on 
immune effector cells can be obtained in different ways 
[5, 6, 34]. For instance, ADO can interfere signals 
mediated by IL-2 receptor by dephosphorylating SHP-2 
and STAT-5 [36]. The consequence is inhibition of TCR-
triggered proliferation and CD25 up-regulation [37]. Other 
modalities of ADO functionalities related to the inhibition 
of cytotoxicity and cytokine production by specific anti-
melanoma T cells have also been reported [8].
The original observations of this work are that: 
i) primary melanoma cell lines inhibit CD4+ and CD8+ 
T cell proliferation, ii) such inhibition is mediated by 
soluble factor(s), and iii) a key role is exerted by ADO. 
These conclusions are supported by substantial evidence. 
On the one hand, specific inhibitors of CD73 and CD38 
partly (but significantly) restored T cell proliferation. 
Such proliferation was not fully restored in the presence 
of these inhibitors, probably because two alternative 
pathways for ADO production are operating on melanoma 
cells. However, we cannot exclude the contribution of 
other immunosuppressive mechanism(s). However, this 
indicates that the function of both molecules, cooperating 
in ADO production, is crucial for melanoma-driven 
inhibition of T cell proliferation.
Secondly, the key role of ADO in such effects on 
T cells was confirmed by the findings that i) CD8+ T 
lymphocytes proliferation was further dampened by 
dipyridamole, a specific inhibitor of nucleoside transporter, 
that causes ADO to accumulate in the extracellular milieu 
and ii) proliferation of T cells was significantly restored 
by pre-treating these cells with specific antagonists of 
ADORs. A third observation is that the anti-proliferative 
effects featured by melanoma cells was different on CD4+ 
and CD8+ T cell subsets. Consequently, proliferation was 
significantly impaired in CD4+ T cells, in effector and 
central memory, and – to a lesser extent −, in naïve T cells. 
Different results were obtained in CD8+ T cells, where 
proliferation of naïve and memory was inhibited more 
than in effector T cells. We hypothesize that this apparent 
discrepancy could be due to a selective expression of ADO 
receptors on these lymphocyte populations.
There are four ADOR subtypes (A1, A2a, A2b 
and A3), that belong to the G-protein-coupled seven-
transmembrane family of cell-surface receptors [5]. A1 
and A2a ADOR (Kd for ADO, ~10−8 to 10−7 M) exhibit 
higher relative affinities for ADO than A2b and A3 
ADOR (Kd for ADO, ~10−6 to 10−5 M). ADOR subtypes 
are coupled to different combinations of G-protein family 
members, namely A1 ADOR to Gi/Go, A2a ADOR to 
Gs/Golf, A2b ADOR to Gs/Gq, and A3 ADOR to Gi/Gq. 
Accordingly, engagement of ADORA2a and A2b activates 
adenyl cyclase, leading to elevated levels of cellular cyclic 
AMP (cAMP). Instead, A1 and A3 stimulation inhibits 
adenyl cyclase, resulting in decreased cellular levels of 
cAMP. In addition, all ADOR subtypes couple to mitogen-
activated protein kinase (MAPK) pathways. The final 
effects of extracellular ADO on lymphocyte function are 
dictated by the expression of distinct surface ADOR, as 
well as by their relative affinities for ADO.
The ADORA2a and A2b were differentially 
expressed by the subsets whose proliferation is less 
inhibited by melanoma cell lines (i.e. naïve CD4+ T cells 
and effector CD8+ T cells) when compared to other 
cell subsets. These receptors are endowed with anti-
proliferative effects on T cells [38] by modulating cAMP, 
MAPK, ERK1-2 and JAK/STAT pathways. Thus, the 
correlation between high expression of these receptors and 
the low inhibition of proliferation induced by melanoma 
cells might be related to a different intracellular pathway 
activated by ADO in naïve CD4+ T cells and effector CD8+ 
T cells compared to the other subsets. Further evidence 
comes from the observation that the phosphorylation 
of S6 ribosomal protein, p38 and Stat1 in CD4+ T cells 
activated in the presence of ADO was significantly 
lower in memory than in naïve CD4+ T lymphocytes. 
S6 ribosomal protein is reported as a regulator of mRNA 
and cell proliferation [39], while p38 and Stat1 are key 
factors in signal transduction in response to cytokines and 
other stimuli [40, 41]. Thus, it is reasonable to conclude 
that the inhibition of memory CD4+ T lymphocytes 
proliferation mediated by ADO occurs through a different 
modulation of cell cytoplasmic signals. ADORA1 subtype, 
that is associated to a reduction in cellular cAMP levels, 
was similarly expressed by all T cell subsets.
Emerging evidence indicates that metabolic signals 
regulate AMP-activated protein kinase (AMPK) and 
mTOR thus directing T lymphocyte-mediated immune 
responses [37]. In line with this, AMPK activation 
regulates cell proliferation by inhibition of mTOR 
signalling [42]. AMPK is activated after phosphorylation 
of the α-catalytic subunit by the glycogen synthase 
kinase-3 (GSK3) induced by AMP, that in turn inhibits 
mTOR activity, a major regulator of translation initiation 
and cell proliferation. Thus, the conversion of AMP into 
ADO provokes antagonistic effects on AMPK activation. 
Some of the most characterized downstream effectors 
of mTOR is the 70 kDa ribosomal protein S6 kinase 1 
(p70S6K) and S6rp. Non-phosphorylated AMPK might be 
unable to induce phosphorylation of essential components 
of mTOR pathway (S6rp, p70S6K) [43], with a reduction 
of cell proliferation (Figure 8). Phosphorylation of the 
AMPK/mTOR/p70S6K/rpS6 protein axis was also 
significantly lower in memory than in naïve CD4+ 
T cells, with reduced proliferation in the presence of 
melanoma cells. It is also known that AMPK-deficient 
CD8+ T cells produce more inflammatory cytokines 
than wild-type T cells. This feature is not present in 
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AMPK-deficient CD4+ T cells, suggesting that AMPK 
is mainly a negative regulator of CD4+ T cell activation. 
Finally, we have demonstrated that the phosphorylation of 
Raptor was increased by ADO in naïve (but not in memory) 
T cells. Since this regulatory protein is involved in mTOR-
mediated phosphorylation of 4E-BP1 and p70 S6K, 
leading to cell cycle progression, these data may further 
explain the very low inhibition of T cell proliferation 
induced by ADO in naïve CD4+ T cells.
The results of this study demonstrate that primary 
melanoma cells inhibit T cell proliferation by producing 
ADO from distinct and functional ectoenzymatic 
pathways. Such inhibition is more effective on T cell 
subsets prevalently involved in anti-tumor immune 
response (i.e., central and effector memory CD4+ T cells 
and memory CD8+ T cells). The clinical relevance of this 
observation is that ADO is a key component of a strategy 
adopted by human melanoma cells to escape the specific 
Figure 8: Summary of the effects of ADO on the AMPK/mTOR/p70S6K/rpS6 protein axis in T lymphocytes. Positive 
signaling through mTOR, a downstream effector of AMPK, regulates protein translation and cell proliferation. mTOR activity can be 
monitored by the phosphorylation status of AMPK, S6K or its downstream substrate rp6S. ADO inhibition of the phosphorylation status 
of the AMPK/mTOR/S6K/rpS6 components of the signaling cascade may decrease lymphocyte protein synthesis and cell proliferation. 
Abbreviations: AMPK, AMP-activated protein kinase; S6K, p70 ribosomal S6 kinase 1; elF4B, eukaryotic translation initiation factor; 
mTOR, mammalian target of rapamycin; Raptor, regulatory-associated protein of mTOR.
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immune response. These data may pave the way to the 
development of novel therapeutic strategies for blocking 
ectoenzymes involved in ADO production, thereby 
restoring a local potent anti-tumor immune response.
MATERIALS AND METHODS
Melanoma cell lines and T cell isolation
MECA, METRAV, MEPA, MECO, MEMO and 
MEOL are primary melanoma cell lines established from 
patients who underwent surgical resection of skin or lymph 
node metastases at Istituto Nazionale Ricerca sul Cancro 
(Genoa), as previously described [28]. The FO1 melanoma 
cell line was purchased by ATCC. Melanoma cell lines 
were cultured in RPMI medium (Sigma Chemical 
Company) supplemented with 10% FBS (Sigma).
PB samples were obtained from normal donors 
afferent at Blood Bank of Istituto Giannina Gaslini 
(Genoa). CD4+ and CD8+ T cells were isolated by 
incubating whole blood samples with RosetteSepTM 
Human CD4+ T cell or CD8+ T cell enrichment cocktail 
(StemCell Technologies) following manufacturer’s 
protocol. Untouched CD4+ T cell or CD8+ T cells were 
then obtained by Ficoll-Hypaque (Sigma) density gradient 
centrifugation.
Naïve, effector memory and central memory CD4+ 
T cell subsets and naïve, effector and memory CD8+ T cell 
subsets were isolated from PB mononuclear cells (MNC) 
obtained by Ficoll-Hypaque (Sigma Chemical Company) 
density gradient centrifugation, using the following 
isolation kits (Myltenyi Biotec): Pan naïve T cells 
Isolation kit, naive CD4+ T Cell Isolation Kit II, CD4+ 
Effector Memory T Cell Isolation Kit, CD8+CD45RA+ 
Effector T Cell Isolation Kit, CD4+ Central Memory T 
Cell Isolation Kit and CD8+ Memory T Cell Isolation Kit. 
Cells were isolated following manufacturer’s protocol. 
Naïve CD8+ T cells were obtained using pan naïve T cells 
Isolation kit and subsequently naive CD4+ T Cell Isolation 
Kit II, collecting the negative fraction.
For intracellular signaling experiments, naïve CD4+ 
T cells were obtained as described above from untouched 
total CD4+ T cells. Memory CD4+ T cells were obtained as 
positive fraction from the same cell preparation.
Flow cytometric analysis
Evaluation of the expression of ectoenzymes was 
performed on melanoma cell lines using the following 
monoclonal (m)Abs generated in our lab and FITC- or 
APC-conjugated by Aczon (Bologna, Italy): anti-CD38 
(#IB4), anti-CD73 (#CB73), anti-CD157 (#SY/11B5), 
anti-CD203a/PC-1 (#3E8, kindly provided by J. Goding). 
CD39 expression was analyzed using anti-CD39 PE-Cy7 
mAb (eBioscience). FITC- or APC-conjugated irrelevant 
isotype-matched mAbs were purchased from Beckman 
Coulter.
The expression of ADOR was evaluated on 
total CD4+ or CD8+ T cells isolated as previously 
described from five normal donors, gating on naïve 
(CD27+CD45RA+), CD4+ central memory/CD8+ 
memory (CD27+CD45RA−) or CD4+ effector memory/
CD8+ effector (CD27−CD45RA−) T cells, using the 
following antibodies: anti-CD45RA PC7, anti-CD27 APC 
(eBiosciences), purified rabbit polyclonal anti-ADORA1 
(LifeSpan Biosciences, Inc.), rabbit polyclonal anti-
ADORA2a (Thermo Scientific), goat polyclonal anti-
ADORA2b (Santa Cruz Biotechnology). FITC-conjugated 
goat-anti rabbit Ig (Abcam) and swine-anti goat Ig (Life 
Technologies) were used as secondary reagents.
Cells were run on Gallios cytometer and analyzed 
using Kaluza software (Beckman Coulter). Data were 
expressed as mean relative of fluorescence intensity 
(MRFI), obtained as follows: mean fluorescence obtained 
with specific mAb/mean fluorescence obtained with 
irrelevant isotype-matched mAb. In some experiments, 
data were expressed as percentage of positive cells.
ADO production by melanoma cell lines
Melanoma cell lines (5x105 cells/well) were 
cultured in 0,1% glucose PBS at 37°C and 5% CO2 in 
24 well plates (Costar Corning), in the presence (or 
absence) of AMP, ADPR, ATP or NAD+ (20 or 50 μM). 
In some experiments, cells were treated for 30 min with 
EHNA [44] (inhibitor of ADO deaminase, 100 μM) 
before being cultured with the substrates. Supernatants 
were collected after 5, 30 or 45 min and acetonitrile 
(ACN) was immediately added (1:2 ratio at 4°C) to 
stabilize ADO. Samples were then centrifuged at 12,000 
rpm and supernatants were collected and stored at −80°C 
until use. The presence of ADO, AMP, ATP and NAD+ 
was investigated by HPLC assay.
HPLC analysis
Chromatographic analysis was performed with an 
HPLC System (Beckman Gold 126/166NM, Beckman 
Coulter) equipped with a reverse-phase column (Synergi 
Fusion C18, 5 μm; 150 × 4.5 mm, Phenomenex). 
The nucleotides and nucleosides were separated using a 
pH 5.1 mobile-phase buffer (0.125 M citric acid and 0.025 
M KH2PO4) along with 8% acetonitrile (Sigma Aldrich) 
over 10 min at a flow rate of 0.8 mL/min. UV absorption 
spectra were measured at 254 nm. HPLC-grade standards 
used to calibrate the signals were dissolved in AIM V 
serum-free medium (Invitrogen, Paisley, UK), pH 7.4, 
0.2 μm sterile-filtered and injected in a buffer volume 
of 20 μL. The retention times (Rt, in min) of standards 
were: AMP, 2.15; NAD+, 2.8; ADPR, 3.2; and ADO; 5.56. 
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Peak integration was performed using a Karat software 
(Beckman Coulter).
ACN-treated melanoma cell supernatants (see 
above) were evaporated by speed-vac, reconstituted in 
mobile-phase buffer, and assayed by HPLC.
The qualitative identity of HPLC peaks was 
confirmed by co-migration of known reference standards. 
The presence of ADO was also confirmed by spiking 
standard (50 μM ADO), followed by chromatography. 
Quantitative measurements were inferred by comparing the 
peak area of samples with calibration curves for peak areas 
of each standard compound. Product concentrations were 
expressed as nmol/30 min/number of cells (5x105 cells).
T cell proliferation
T cell proliferation was assessed by 
Carboxyfluorescein succinimidyl ester (CFSE) dilution 
assay. Briefly, T cells were stained with CFSE (Invitrogen, 
1 μg/ml, 15 min at 37°C), washed, and then cultured in 
RPMI medium added along with 10% FBS at 37°C 
and 5% CO2, alone or in the presence of anti-CD3/anti-
CD28 mAb coated beads (T cell activation/expansion 
kit, Miltenyi Biotec). Stimulated T cells were cultured in 
24 or 96 flat-bottom well plates (Costar Corning) in the 
presence or absence of melanoma cell lines (at 1:8 or 1:16 
melanoma:T cell ratios). In some experiments, melanoma 
cell lines were treated for 30 min with the following 
specific inhibitors before being cultured with T cells at 
1:16 melanoma:T cell ratio: 10 μM kuromanin [45] (an 
inhibitor of CD38, Sigma Aldrich), 50 μM dipyridamole 
[46] (an inhibitor of nucleoside transporter, Sigma 
Aldrich), 300 μM α-β-meADP [47] (an inhibitor of CD73, 
Sigma Aldrich) and 300 μM β-γ-meATP [48] (an inhibitor 
of CD203a/PC-1, Sigma Aldrich). In some experiments, 
CD4+ T cells were cultured 24 well plates (Costar Corning) 
and melanoma cell lines were cultured in the upper 
chamber of a transwell system (Costar Corning), at 1:8 or 
1:16 melanoma:CD4+ T cell ratios. In some experiments, 
CD4+ or CD8+ T cells were treated for 30 min with the 
following specific inhibitors (all purchased from Tocris 
Bioscience) before being cultured with melanoma cells 
at 1:16 melanoma:T cell ratio: SCH58261 (A2a Receptor 
Antagonist), PSB1115 (A2b Receptor Antagonist) and 
PSB36 (A1 Receptor Antagonist).
After 6 days, cells were harvested and washed, and 
then stained with PE-conjugated anti-CD4 or anti-CD8 
mAbs (Beckman Coulter). After additional washes, cells 
were run on Gallios cytometer, and CFSE dilution was 
analyzed gating on CD4+ or CD8+ cells, using Kaluza 
software (Beckman Coulter). In some experiments, cells 
were run on MACSQuant Analyzer (Miltenyi Biotec) 
and analyzed using FlowJo X Data Analysis Software 
(FlowJo LLC). Data were expressed as % of proliferating 
cells. In some experiments, data were expressed as 
% of proliferation inhibition, calculated as follows: 
% of proliferating cells in the absence of melanoma 
cells - % of proliferating cells in the presence of melanoma 
cells/% of proliferating cells in the absence of melanoma 
cells. In some experiments, data were expressed as % of 
variation, calculated as follows: (% of proliferating cells 
in the presence of inhibitor/% of proliferating cells in the 
absence of inhibitor) x 100.
Intracellular signaling
Naïve and memory CD4+ T cells were stimulated 
overnight with anti-CD3/anti-CD28 beads (Myltenyi 
Biotec) following manufacturer’s protocol. Cells were then 
washed, resuspended in RMPI medium, and incubated 
at 37°C in the presence or absence of 50 μM ADO 
(for 15 min). IL-2 (Proleukin, Novartis Pharm S.p.A., 
100 U/ml) was then added and cells were incubated at 
37°C for additional 15 min. Cells were then washed with 
PBS and lysed using PathScan Intracellular Signaling 
Lysis Buffer (Cell Signaling Technologies). Protein 
concentration was assessed using a BCA assay (BioRad). 
Cell lysates were diluted at a protein concentration of 
0.7 mg/ml and intracellular signaling was investigated 
using PathScan Intracellular Array kit (Cell Signaling 
Technlogies) following manufacturer’s protocol. In some 
experiments, protein lysates (20 μg per lane) were resolved 
on SDS 10% polyacrylamide gels and were transferred 
to nitrocellulose membranes. The membranes were then 
incubated with anti-Phospho-Raptor or anti-Phospho-Rictor 
rabbit polyclonal antibodies (Cell Signaling, MA, USA). 
Peroxidase-conjugated goat anti-rabbit polyclonal antisera 
was used as secondary reagent (Santa Cruz Biotechnology). 
Immune complexes were visualized with the use of a 
Supersignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, IL, USA) according to the manufacturer’s 
instructions, and were normalized to internal controls (a 
mouse monoclonal antibody against alpha-tubulin, Cell 
Signaling).
Protein levels were quantified by scanning 
densitometry of the autoradiography films using VersaDoc 
3000 Gel Imaging System (BioRad, Hercules, CA, USA) 
and normalized over the housekeeping protein levels 
(relative density). Results are expressed as % of fold 
increase, calculated as follows: [(relative intensity of spot 
obtained in the presence of ADO - relative intensity of 
spot obtained in the absence of ADO)/relative intensity 
of spot obtained in the absence of ADO)] ×100. In some 
experiments, data were expressed as relative density.
Statistical analysis
Statistical analysis was performed using Prism 5.03 
software (GraphPad Software). Gaussian distribution 
of data was analyzed using Kolmogorov-Smirnov 
test. The Student t test or Mann-Whitney test was 
used to compare data, depending on data distribution. 
The significance range as follows: *p < 0.05 (significant), 
**p < 0.005, and ***p < < 0.0005.
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